These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 27696259)

  • 1. Targeting the Bone Marrow Microenvironment.
    Moschetta M; Kawano Y; Podar K
    Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
    Yao H; Cheng L; Chen D; Zhang Q; Qiu L; Ren SH; Dou BT; Wang H; Huang J; Fan FY
    Expert Rev Anticancer Ther; 2023; 23(8):807-815. PubMed ID: 37343305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple Myeloma and the Immune Microenvironment.
    Kawano Y; Roccaro AM; Ghobrial IM; Azzi J
    Curr Cancer Drug Targets; 2017; 17(9):806-818. PubMed ID: 28201978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the bone marrow microenvironment in multiple myeloma.
    Kawano Y; Moschetta M; Manier S; Glavey S; Görgün GT; Roccaro AM; Anderson KC; Ghobrial IM
    Immunol Rev; 2015 Jan; 263(1):160-72. PubMed ID: 25510276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
    Lee HC; Weber DM
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
    Shay G; Hazlehurst L; Lynch CC
    J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Microenvironment for Treating Multiple Myeloma.
    Neumeister P; Schulz E; Pansy K; Szmyra M; Deutsch AJ
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
    Varga C; Laubach JP; Anderson KC; Richardson PG
    Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma.
    Ribatti D; Nico B; Vacca A
    Oncogene; 2006 Jul; 25(31):4257-66. PubMed ID: 16518413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
    Ho M; Xiao A; Yi D; Zanwar S; Bianchi G
    Curr Oncol; 2022 Nov; 29(11):8975-9005. PubMed ID: 36421358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The microenvironment and molecular biology of the multiple myeloma tumor.
    Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
    Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
    Asimakopoulos F; Hope C; Johnson MG; Pagenkopf A; Gromek K; Nagel B
    J Leukoc Biol; 2017 Aug; 102(2):265-275. PubMed ID: 28254840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow microenvironment and the identification of new targets for myeloma therapy.
    Podar K; Chauhan D; Anderson KC
    Leukemia; 2009 Jan; 23(1):10-24. PubMed ID: 18843284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.
    Uckun FM
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipose, Bone, and Myeloma: Contributions from the Microenvironment.
    McDonald MM; Fairfield H; Falank C; Reagan MR
    Calcif Tissue Int; 2017 May; 100(5):433-448. PubMed ID: 27343063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapies for multiple myeloma.
    Podar K; Tai YT; Hideshima T; Vallet S; Richardson PG; Anderson KC
    Expert Opin Emerg Drugs; 2009 Mar; 14(1):99-127. PubMed ID: 19249983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.